Saturday, February 9, 2019
Program is subject to change
| 7:00 am | Registration and Continental Breakfast |
| 7:50 | Welcome and Overview / Pre-Program Test Philip J. Rosenfeld, MD, PhD, Harry W. Flynn, Jr., MD, and Thomas A. Albini, MD |
| Session I: Age-Related Macular Degeneration Moderators: Philip J. Rosenfeld, MD, PhD and Zohar Yehoshua, MD, MHA |
|
| 8:00 | Bioenergetics, Metabolism and Macular Degeneration Philip Luthert, MBBS |
| 8:10 | New Data on the Prevalence of AMD Professor Jean-FrancoisKorobelnik |
| 8:20 | 10 Year Follow-up of AREDS2 and More Emily Y. Chew, MD |
| 8:30 | Natural History of Geographic Atrophy Secondary to Age-Related Macular Degeneration: Proxima A and B Clinical Trial Results Nancy M. Holekamp, MD |
| 8:40 | Can Genetics Help Identify Individuals With Intermediate AMD at High Risk of Progression? Johanna M. Seddon, MD, ScM |
| 8:50 | Common Age-related Macular Degeneration Genetic Risk Variants and Geographic Atrophy Lesion Growth in the Phase 3 Lampalizumab Trials: Update Karl G. Csaky, MD, PhD |
| 9:00 | Addressing the Cuticular Drusen Epidemic Lawrence A. Yannuzzi, MD |
| 9:10 | Structural/Dynamic/Functional (OCT/OCTA/MP) Assessment of the Macula Brandon Lujan, MD |
| 9:20 | Ultrahigh Speed and Ultrahigh Resolution OCT for Investigating the Outer Retina and Choriocapillaris James G. Fujimoto, PhD |
| 9:30 | Quantitative Assessment of the Choroidal Vasculature Using Swept Source OCTA Ruikang Wang, PhD |
| 9:40 | OCTA of the Choriocapillaris in AMD Nadia K.Waheed, MD |
| 9:50 | SS-OCTA Imaging of Choriocapillaris Flow Deficits in Non-Exudative AMD and Their Correlation with Disease Progression Philip J. Rosenfeld, MD, PhD |
| Session II: Non-Exudative AMD Moderators: Thomas A. Albini, MD and Lawrence J. Singerman, MD, FACS |
|
| 10:00 | Retina Trends – A VC’s Perspective Emmett T. Cunningham, Jr., MD, PhD, MPH |
| 10:10 | OCT Risk Factors for Development of Late AMD: A Fellow Eye Analysis from the HARBOR Trial SriniVas Sadda, MD |
| 10:20 | Nanosecond Laser Intervention to Slow AMD Progression Robyn Guymer, MBBS, PhD, FRANZCO |
| 10:30 | Soft Drusen Precursors Removed by a Clinical-Stage Apolipoprotein Mimetic Peptide in A Non-human Primate AMD Model Christine A. Curcio, PhD, FARVO |
| 10:40 | Kamuvudines for Macular Degeneration Jayakrishna Ambati, MD |
| 10:50 | Update on Gene Therapy for Complement Inhibition: 1 Year Results of A Phase 1 Study Jay S. Duker, MD |
| 11:00 | Update for the ReCLAIM Trial: Elamipretide for the Treatment of Vision Loss in Drusen and Noncentral GA Scott W. Cousins, MD |
| 11:10 | TOGA-- Baseline Characteristics and Preliminary Safety Data Elias Reichel, MD |
| 11:20 | Stem Cell Derived RPE Transplantation Surgery for Geographic Atrophy Amir H. Kashani, MD, PhD |
| 11:30 | C3 inhibition in Geographic Atrophy Cedric G. Francois, MD, PhD |
| Session III: High Risk Non-Exudative AMD Moderators: Harry W. Flynn, Jr., MD and Jaclyn L. Kovach, MD |
|
| 11:40 | The Spectrum of Treatment-Naive Subclinical Macular Neovascularization Giuseppe Querques, MD, PhD |
| 11:50 | Two-Year SS-OCTA Incidence and Natural History of Subclinical Neovascularization in Age-Related Macular Degeneration Philip J. Rosenfeld, MD, PhD |
| 12:00 pm | Pearls from PROCON: What Have We Learned in Year 1 of this 2 Year Trial Jeffrey S. Heier, MD |
| 12:10 | Clear Study of Mobile App to Monitor Visual Function in DR and AMD Lawrence J. Singerman, MD, FACS |
| 12:20 | The Future of AMD Management will Include Home OCT Monitoring by Our Patients Anat Loewenstein, MD, MHA |
| 12:30 | Prevention of Exudative CNV in Eyes with High Risk AMD: Theoretical and Practical Challenges in Clinical Trial Design Daniel F. Martin, MD |
| 12:40 | Lunch |
| Session IV: Macular Neovascularization: Imaging and Emerging Therapies Moderators: Philip J. Rosenfeld, MD, PhD and Ninel Z. Gregori, MD |
|
| 1:20 | Vascular Maturity of Choroidal Neovascularization Evaluated by OCTA Hiroko Terasaki, MD, PhD |
| 1:30 | Polyps in Polypoidal Choroidal Vasculopathy Appear as Tangled Vascular Structures Using Swept-Source OCT Angiography Fenghua Wang, PhD |
| 1:40 | Variations of Choroidal Thickness in CNV Bruno Lumbroso, MD |
| 1:50 | Choroidal Neovascularization: Jekyll or Hyde? Jason S. Slakter, MD |
| 2:00 | Can Exudative AMD Treat Itself? K. Bailey Freund, MD |
| 2:10 | What We Have Learned About Integrins and Their Mechanism of Action David S. Boyer, MD |
| 2:20 | Pan-VEGF Blockade for AMD Peter K. Kaiser, MD |
| 2:30 | KSI-301: Update on Phase 1 Studies with a First in Class Antibody-Biopolymer Conjugate for Treatment of Wet AMD, DME, and Other Retinal Vascular Diseases Diana V. Do, MD |
| 2:40 | Sustained Release Ranibizumab Therapy: The Phase 2 LADDER Study Carl D. Regillo, MD, FACS |
| 2:50 | Phase 1 Results of GB-102: A Novel Bioabsorbable Sustained-release IVT Depot Formulation of Sunitinib for nAMD (ADAGIO Study) David S. Boyer, MD |
| 3:00 | Subretinal Injection of AAV8 Expressing an Anti-VEGF Protein in Patients with Neovascular AMD Peter A. Campochiaro, MD |
| 3:10 | Gene Therapy for Neovascular AMD : Intravitreal Delivery of AAV-7m8 vectors. David M. Brown, MD |
| Session V: Macular Neovascularization, Diabetes, and Anti-VEGF Therapy Moderators: Harry W. Flynn, Jr. MD and Justin H. Townsend, MD |
|
| 3:20 | Advances in the Development of an Assisted Intravitreal Injection System Stephan Michels, MD |
| 3:30 | Brolucizumab versus Aflibercept for Neovascular AMD: 96-week Expanded Anatomical Outcomes from HAWK and HARRIER" Pravin U. Dugel, MD |
| 3:40 | The Social Cost of Blindness Due to AMD and Diabetes Andrew A. Moshfeghi, MD, MBA |
| 3:50 | Retinal Neurodegeneration and Microangiopathy as Mechanisms of Early DR Yu Seung-Young, MD |
| 4:00 | Relation Between Peripheral and Central Retinal Capillary Non Perfusion is Non Linear in Diabetic Microvascular Disease Usha Chakravarthy, MD |
| 4:10 | Widefield OCT-A in Diabetic Retinopathy Harry W. Flynn, Jr., MD |
| 4:20 | Higher Order Assessment of Optical Coherence Tomography for Quantitative Retinal Features in the VISTA DME Study Justis P. Ehlers, MD |
| 4:30 | Intravitreal Aflibercept for Moderately Severe to Severe Non-Proliferative Diabetic Retinopathy (NPDR): 1-Year Outcomes of the Phase 3 PANORAMA Study Charles C. Wykoff, MD |
| 4:40 | Comparison of wide-field OCTA and Ultrawide-field FA Assessment of Capillary Perfusion in Diabetic Retinopathy After Anti-VEGF Therapy Ramin Tadayoni, MD, PhD |
| 4:50 | Preclinical and Emerging Clinical Evidence Supporting the Rationale for Targeting Angiopoietin2 in Diabetic Eye Disease Peter A. Campochiaro, MD |
| 5:00 | Manipulating the Tie2 Pathway in Diabetic Retinopathy Peter K. Kaiser, MD |
| Session VI: Retinal Vascular Diseases, Uveitis, and Retinal Degenerations Moderators: Philip J. Rosenfeld, MD, PhD and Janet L. Davis, MD |
|
| 5:10 | Inflammation in Retinal Vascular Diseases: The Role of Interleukin-6 in Age-Related Macular Degeneration and Diabetic Macular Edema Quan Dong Nguyen, MD |
| 5:20 | The Long-Term Physical Stability, Sterility and Anti-VEGF Bio-Activity of Repackaged Bevacizumab in 2 mL Glass Vials: Findings from SCORE2 Michael S. Ip, MD |
| 5:30 | Anti-VEGF Therapy in ROP Darius M. Moshfeghi, MD |
| 5:40 | ZIPANGU: A Comparison Study of Anti-VEGF Therapy with or Without OCTA Guided Focal/Grid Laser for Macular Edema Secondary to BRVO Toshinori Murata, MD, PhD |
| 5:50 | Macular Pigment: An Important Technique to Detect Mueller’s Cells Diseases Giovanni Straurenghi, MD |
| 6:00 | Is MacTel a “Serine-Opathy? Martin Friedlander, MD, PhD |
| 6:10 | A Deep Learning Approach to Quantify Ellipsoid Zone Loss in MacTel2 and Other Macular Diseases Glenn J. Jaffe, MD |
| 6:20 | Suprachoroidal Delivery of Steroids in Uveitis Thomas A. Albini, MD |
| 6:30 | EYS606 - Non Viral Gene Therapy for the Treatment of Non Infectious Uveitis Sunil K. Srivastava, MD |
| 6:40 | Treatments and Clinical Trials in Inherited Retinal Degenerations Byron L. Lam, MD |
| 6:50 | Clinical Trials in Stargardt Disease Carel B. Hoyng, MD |
| 7:00 | Post-Program Test and Closing Remarks |
| 7:05 | Adjourn/Cocktail Reception |